Newsroom
  • Press Releases
  • Presentations
Investors
  • Overview
  • Warrant Exercise Inquiries
  • Restricted Stock Inquiries
  • Notice to Stockholders
  • News / Events
  • Company Information
  • Financial Information
  • Stock Data
  • SEC Filings
  • Corporate Governance
Clinical Trial Enrollment
  • Triple-Negative Breast Cancer
  • COVID-19 Mild to Moderate
  • COVID-19 Severe or Critical
  • COVID-19 Long-Haulers
Contact

CytoDyn Inc.

  • Home
  • About CytoDyn
    • Meet CytoDyn
  • Our Science
  • Pipeline
    • Overview
    • HIV
    • Cancer
    • GVHD
    • COVID-19
  • Expanded Access
  • Our Team
    • Management Team
    • Board of Directors
  • Careers
    • Now Hiring
  • Scientific Board of Advisors
  • Newsroom
  • Investors
  • Clinical Trial Enrollment
  • Contact
Latest News

FOR THE LATEST DEVELOPING NEWS Click Here

Hospitals Enrolling COVID-19 Severe-to-Critical

Investment Community Webcast on Wednesday, April 7

Antibody-based strategies in HIV therapy

Leronlimab in International Journal of Infectious Diseases

Manuscript Accepted by Infectious Diseases Society of America

Into the Looking Glass: Post-Viral Syndrome Post COVID-19

Local drug trial provides hope for COVID ‘long-haulers’

Leronlimab’s Mechanism of Action in COVID-19 Published

Leronlimab role in COVID-19

Experimental Drugs Aim to Treat Long-Haul Covid Patients

Leronlimab and Long-Haulers

Research on Critically Ill COVID-19 Patients Published in Journal of Translational Autoimmunity

Case Study of Critically Ill Person with COVID-19 on ECMO Successfully Treated with Leronlimab Published in Journal of Translational Autoimmunity

Dr. Seethamraju’s Presentation at Special isirv-AVG Virtual Conference

Press Releases

Newsroom

Newsroom

  • Press Releases
  • Presentations

CytoDyn Appoints Dr. Scott A. Kelly as Chairman of the Board

Dec 12, 2018 6:00am EST

CytoDyn to Hold Investment Community Conference Call on December 12, 2018

Dec 06, 2018 6:00am EST

CytoDyn’s Prostate Cancer Prognostic Test Demonstrates Substantial Added Value to Gleason Score in Predicting Patient Outcomes

Nov 29, 2018 8:58am EST

CytoDyn to Present at Two Investment Conferences in December

Nov 27, 2018 6:00am EST

CytoDyn Announces Initiation of Metastatic Triple Negative Breast Cancer Trial and Reiterates Phase 3 Goal in Cancer

Nov 26, 2018 6:00am EST

USAN Council Assigns Leronlimab as the Official Name for CytoDyn’s PRO 140

Nov 20, 2018 6:00am EST

CytoDyn Completes Acquisition of ProstaGene and Names Dr. Richard G. Pestell to Board of Directors

Nov 19, 2018 6:00am EST

Data from PRO 140 (leronlimab) HIV Monotherapy Trial Selected for Presentation at CROI 2019

Nov 16, 2018 6:00am EST

CytoDyn’s PRO 140 (leronlimab) HIV Monotherapy Trial Results Show 92% Responder’s Rate at 700 mg Dose

Nov 13, 2018 6:00am EST

CytoDyn Files IND and Protocol for Phase 1b/2 Clinical Trial in Metastatic Triple-Negative Breast Cancer with PRO 140 (Leronlimab)

Nov 05, 2018 6:00am EST
RSS
  • Prev
    • 1...
    • 17
    • 18
    • 19
    • 20
    • 21
    • 22
    • 23
    • 24
    • 25
    • 26
    • ...35
    Next
    © 2021 CytoDyn Inc. All Rights Reserved.
    • Twitter
    • Facebookj
    Privacy Policy Disclaimer Sitemap